TCTR20220204005Not yet recruitingPhase 2
Efficacy and safety of Herbal Drink in mild to severe COVID-19 patients: pilot study
Giving Mind Nirvana Soul Foundation0 sites100 target enrollmentStarted: February 4, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20 Years to N/A (No limit) (—)
- Sex
- All
Inclusion Criteria
- •1. 20 (minimum) years of age 2. Diagnosis of COVID-19 infection confirmed by RT-PCR test for SAR-CoV-2 3. mild to severe COVID-19 symptoms 4. No uncontrollable underlying disease 5. Onset of symptoms is within 5 days or positive RT-PCR for SAR-CoV-2 within 5 days 6. Signed informed consent provided by patient 7. Willing to stay at research site at least 10 days
Exclusion Criteria
- •1. COVID19 positive based on Antigen test but PCR negative 2. Severe or critical clinical conditions (Glasgow coma scale less than 14) 3. Severe COVID-19 4. Patient who is on mechanical ventilator 5. Abnormal chest x-ray 6. Dyspnea or respiratory rate above 30 per minute 7. Hypoxia or oxygen saturation less than 96 percent 8. Underlying diseases including Diabetes mellitus, uncontrollable hypertension 9. Abnormal liver function test: ALT/AST increased 5 times higher than the upper limit of normal or with Child Pugh C 10. Renal failure or Creatinine clearance (Cockcroft-Gault Equation) less than 30 ml/min or having hemodialysis/peritoneal dialysis 11. Known allergy or hypersensitivity to Herbal Drink 12. Pregnant (female of childbearing age with positive urine pregnancy test) or Lactating female
Investigators
Similar Trials
Not yet recruiting
Phase 2
Efficacy and safety of Herbal Drink in mild to moderate Covid-19 patients: pilot studyconfirmed RT-PCR for SAR-CoV-2 patients with mild to moderate symptomsmild-symptom covid-19 patients, moderate-symptom covid-19 patients, Herbal Drink, Favipiravir, viral clearanceTCTR20211220001Giving Mind Nirvana Soul Foundation100
Not yet recruiting
Phase 2
Efficacy and safety of Herbal Drink in moderate COVID-19 patients: pilot studyconfirmed RT-PCR for SAR-CoV-2 patients with moderate symptomsmoderate-symptom covid-19 patients, Herbal Drink, Favipiravir, viral clearanceTCTR20220125001Giving Mind Nirvana Soul Foundation100
Not yet recruiting
Phase 3
Evaluation of herbal formulation in contact dermatitisCTRI/2023/07/055420Plant Ayu Life Sciences LLP Pune
Not yet recruiting
Phase 2
Clinical evaluation of herbal formulations in adults with acute/chronic pain and inflammatioCTRI/2023/07/055425Plant Ayu Life Sciences LLP Pune
Completed
Phase 3
Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Prospective, Placebo Controlled, Randomized, double-blinded Parallel-Group Comparison for SuperiorityAcute Otitis Media (AOM)H65.0 und H66.0Upper respiratory tract infectionH65.0H66.0Acute serous otitis mediaAcute suppurative otitis mediaDRKS00004569Weber & Weber GmbH & Co. KGBiologische Arzneimittel311